Project Grant R37CA296259
Award Date 8/20/25
Completion Date 7/31/30
Dollars Obligated $449K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- The federal Project Grant award titled "Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia" was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396). The $654,837 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University aims to explore how the VISTA immune checkpoint receptor modulates antileukemia immunity in acute myeloid leukemia (AML). The research objectives are to...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $234,749 to The Ohio State University to conduct a multi-center Phase Ib clinical trial investigating the combination of the Hedgehog inhibitor Vismodegib and the anti-PD-L1 immunotherapy Atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC). The goal is to understand how Hedgehog signaling in tumor-associated macrophages (TAMs) impacts CD8+...
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This Project Grant award of $502,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Case Western Reserve University focused on developing a small-molecule degrader called SISU-102 to target leukemic stem cells (LSCs) in acute myeloid leukemia (AML). The key objectives are to further investigate the impacts of these HSF1 degraders on LSC self-renewal, identify sensitive and resistant AML subtypes, and explore the underlying mechanisms. This...
- This federal Project Grant award of $167,771 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Yale University to investigate a novel glyco-immune checkpoint interaction between VSIG4 and SIGLEC-7 proteins and its impact on cancer immunotherapy. The research aims to elucidate the mechanisms of this human-specific interaction using humanized mouse models, with a focus on its effects on multiple myeloma and acute myeloid leukemia. The...